Corvus Pharmaceuticals
Preço: 11.93Empresa e modelo de negócios
Corvus Pharmaceuticals is a healthcare company focused on developing immuno-oncology therapies for cancer treatment. Its core products include investigational drugs targeting specific cancer pathways, with a primary emphasis on enhancing the immune response against tumors. The company operates in the biotechnology segment, primarily generating revenue through research and development activities and potential future product sales.
Perfil de investimento
The investment profile of Corvus Pharmaceuticals is more aligned with growth investors, given its focus on developing innovative therapies in a high-risk sector. The lack of dividends and the company's current financial performance suggest a higher risk profile, making it less suitable for conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility for potential future gains.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -0.55 Risco
- Surpresa de EPS
- -7.1% pior que o esperado
- Volatilidade 20d
- 4.7% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-03 02:37 | Manter | Vender | scenario_deterioration |
| 2026-06-01 02:35 | Vender | Manter | Weak fundamentals and negative momentum signal high risk. |
| 2026-05-16 02:54 | Manter | Vender | scenario_deterioration |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-04-17 08:42 | Goldman Sachs | Atualizar | — → 40 | 15.04 |
| 2026-01-29 11:45 | Mizuho Securities | Preço-alvo elevado | 20 → 30 | 20.54 |
| 2026-01-22 17:28 | Jefferies | Preço-alvo elevado | 13 → 42 | 25.8 |
Nada ainda